USA flag logo/image

An Official Website of the United States Government

Molecular Haplotyping of Long Genomic Distances of DNA

Award Information

Agency:
Department of Health and Human Services
Branch:
N/A
Award ID:
70857
Program Year/Program:
2004 / SBIR
Agency Tracking Number:
HG003422
Solicitation Year:
N/A
Solicitation Topic Code:
N/A
Solicitation Number:
N/A
Small Business Information
GLC BIOTECHNOLOGY, INC.
GLC BIOTECHNOLOGY, INC. 7362 STOCKWOOD DRIVE SOLON, OH 44139
View profile »
Woman-Owned: No
Minority-Owned: No
HUBZone-Owned: Yes
 
Phase 1
Fiscal Year: 2004
Title: Molecular Haplotyping of Long Genomic Distances of DNA
Agency: HHS
Contract: 1R43HG003422-01
Award Amount: $100,000.00
 

Abstract:

This SBIR project is proposed to commercialize a novel method referred as PDESA for revealing patient's individual haplotypes. Our preliminary data shown that PDESA could reveal haplotypes of sequences of 134kb in length, which is about three times longer than the longest sequence haplotyped using other molecular methods. PDESA is simple, easy to implement, and importantly, it works! Thus, this project is warranted. Phase I of this SBIR project is to further demonstrate the feasibility of PDESA and the specific aims of Phase I are: Aim 1: applying PEDSA to hapiotyping a sequence block near the IBD5 locus to establish the fact that PDESA is indeed, a robust, general molecular method for haplotyping; Aim 2: evaluating the accuracy of PDESA by haplotyping a family with a total of 16 individuals in both the ApoE4 and IBD5 loci; and Aim 3: demonstrating the feasibility of using PDESA to haplotype ultra long distances of genomic DNA (longer than 150kb). The goals in Phase II will be (1) to develop the assays that meet the requirements of clinical applications; (2) to develop rapid, easy kits for haplotyping a number of genes of functional and clinical significance, including both individual and multiplexed assays; (3) to develop assays for haplotyping of potential clinical and commercial value, identified in the scientific literature and/or HAPmap database for genes presumed to have values. By the end of this project, we shall have many well-developed assays that are ready to implement for haplotyping both short and long distances of DNA in an accurate, robust, low-cost, high-throughput manner. Thus, success of this project will not only be of commercial significance to GLC Biotechnology Inc., but also will have profound impacts on many fields, particularly on pharmacogenetics, and personalized medicine.

Principal Investigator:

Baochuan Guo
4403492193
B.GUO@CSUOHIO.EDU

Business Contact:

Baochuan Guo
4403492191
B.GUO@CSUOHIO.EDU
Small Business Information at Submission:

GLC BIOTECHNOLOGY, INC.
GLC BIOTECHNOLOGY, INC. 33175 ROCKFORD DR SOLON, OH 44139

EIN/Tax ID: 300091007
DUNS: N/A
Number of Employees: N/A
Woman-Owned: No
Minority-Owned: No
HUBZone-Owned: No